107 related articles for article (PubMed ID: 18019702)
1. Tailored intermittent therapy of carcinoid.
Kinová S; Duris I; Kratochvíl'ová E; Kovácová E; Koren M
Hepatogastroenterology; 2007 Sep; 54(78):1716-9. PubMed ID: 18019702
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid tumors--somatostatine in the diagnosis and therapy.
Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. [Diurnal rhythm of endogenous somatostatin in patients with carcinoid].
Kinová S; Kovácová E; Kratochvíĺová E; Ondrejka P; Duris I
Cesk Fysiol; 2002 May; 51(2):69-74. PubMed ID: 12053490
[TBL] [Abstract][Full Text] [Related]
5. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
6. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
7. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
8. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
Manfé AZ; Norberto L; Marchesini M; Lumachi F
In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
[TBL] [Abstract][Full Text] [Related]
11. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
[No Abstract] [Full Text] [Related]
12. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
13. [Carcinoid tumors].
Pregun I; Bodoky G; Rácz K; Tulassay Z
Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
[TBL] [Abstract][Full Text] [Related]
14. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
Drange MR; Melmed S
J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
16. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
Rohaizak M; Farndon JR
ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples.
Allen KR; Degg TJ; Anthoney DA; Fitzroy-Smith D
Ann Clin Biochem; 2007 May; 44(Pt 3):300-7. PubMed ID: 17456301
[TBL] [Abstract][Full Text] [Related]
18. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.
Bondanelli M; Ambrosio MR; Zatelli MC; Cavazzini L; Al Jandali Rifa'y L; degli Uberti EC
World J Gastroenterol; 2005 Apr; 11(13):2041-4. PubMed ID: 15801004
[TBL] [Abstract][Full Text] [Related]
19. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
20. Metastatic carcinoid tumour of the heart.
Debouverie O; Vaquette B; Hervochon JM
Arch Cardiovasc Dis; 2010; 103(8-9):491-2. PubMed ID: 21074130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
